Skip to main content
Top
Appendix
Available only for authorised users
Literature
1.
go back to reference Rosiñol L, Beksac M, Zamagni E et al (2021) Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 194(3):496–507CrossRefPubMed Rosiñol L, Beksac M, Zamagni E et al (2021) Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol 194(3):496–507CrossRefPubMed
2.
go back to reference Gao S, Li Q, Dong F et al (2022) Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study. Leuk Res 115:106793CrossRefPubMed Gao S, Li Q, Dong F et al (2022) Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study. Leuk Res 115:106793CrossRefPubMed
3.
go back to reference Lee SE, Kim JH, Jeon YW et al (2015) Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol 94(3):445–452CrossRefPubMed Lee SE, Kim JH, Jeon YW et al (2015) Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol 94(3):445–452CrossRefPubMed
4.
go back to reference Varettoni M, Corso A, Pica G et al (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21(2):325–330CrossRefPubMed Varettoni M, Corso A, Pica G et al (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21(2):325–330CrossRefPubMed
5.
go back to reference Beksac M, Seval GC, Kanellias N et al (2020) A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 105(1):201–208CrossRefPubMedPubMedCentral Beksac M, Seval GC, Kanellias N et al (2020) A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 105(1):201–208CrossRefPubMedPubMedCentral
6.
go back to reference Li G, Song YP, Lv Y et al (2021) Clinical characteristics and prognostic analysis of multiple myeloma with extramedullary disease: A SEER-based study. J Oncol 2021:6681521PubMedPubMedCentral Li G, Song YP, Lv Y et al (2021) Clinical characteristics and prognostic analysis of multiple myeloma with extramedullary disease: A SEER-based study. J Oncol 2021:6681521PubMedPubMedCentral
7.
go back to reference Wang Y, Liu A, Xu T et al (2022) Bone-related extramedullary disease in newly diagnosed myeloma patients is an independent poor prognostic predictor. Clin Med Insights Oncol 16:11795549221109500CrossRefPubMedPubMedCentral Wang Y, Liu A, Xu T et al (2022) Bone-related extramedullary disease in newly diagnosed myeloma patients is an independent poor prognostic predictor. Clin Med Insights Oncol 16:11795549221109500CrossRefPubMedPubMedCentral
8.
go back to reference Montefusco V, Gay F, Spada S et al (2020) Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 105(1):193–200CrossRefPubMedPubMedCentral Montefusco V, Gay F, Spada S et al (2020) Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica 105(1):193–200CrossRefPubMedPubMedCentral
9.
go back to reference Yang JZ, Li Y, Sun LX et al (2014) Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients. Pathol Res Pract 210(9):586–590CrossRefPubMed Yang JZ, Li Y, Sun LX et al (2014) Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients. Pathol Res Pract 210(9):586–590CrossRefPubMed
10.
go back to reference Yang JZ, Lian WG, Sun LX et al (2016) High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival. Pathol Res Pract 212(3):210–216CrossRefPubMed Yang JZ, Lian WG, Sun LX et al (2016) High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival. Pathol Res Pract 212(3):210–216CrossRefPubMed
Metadata
Title
Negative effect of paraskeletal plasmacytoma on survival of patients with transplant-ineligible newly diagnosed multiple myeloma
Authors
Junzhe Wang
Xiaoning Song
Xian Zhang
Han Liu
Meirong Zang
Dianwen Qi
Jinqiao Zhang
Lixia Sun
Publication date
16-01-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 4/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05622-1

Other articles of this Issue 4/2024

Annals of Hematology 4/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare